Telix gains FDA Fast Track status for pre-biopsy prostate imaging

FDA Fast Track lifts regulatory momentum

Telix Pharmaceuticals Limited (ASX:TLX, NASDAQ: TLX) has received FDA Fast Track designation for BiPASS, a program testing 68Ga-PSMA-PET imaging alongside MRI before prostate biopsy. The designation gives Telix more frequent interaction with the US regulator and may enable an expedited review of the planned New Drug Application.

That is a meaningful regulatory step, but not a marketing approval. Telix has completed enrolment in the Phase 3 BiPASS study and says it has positively engaged with the FDA on the NDA pathway. The company is now planning its submission, without providing a filing date or topline trial results in the announcement.

BiPASS targets unnecessary prostate biopsies

The clinical proposition is straightforward: use imaging to improve the decision about who should undergo biopsy, and where that biopsy should be targeted. Telix says more than three million prostate biopsies are performed globally each year, with up to 75% producing a negative result. BiPASS is not designed to remove biopsy from the diagnostic pathway where it benefits the patient, but to make that pathway more selective.

The program builds on the PRIMARY and PRIMARY2 studies, which Telix says found that combining 68Ga-PSMA-PET with MRI significantly improved detection of clinically significant prostate cancer while reducing unnecessary biopsies by almost 50%. Those findings provide the rationale for the pivotal study, although the announcement does not report whether BiPASS has reproduced those results.

Approval and commercial questions remain open

If approved, the proposed NDA pathway could broaden access to 68Ga-PSMA-PET imaging across a substantially larger patient population. Telix’s Illuccix and Gozellix are already approved for certain prostate cancer imaging uses, including suspected metastasis and recurrence, but their use before biopsy remains investigational and has not been approved by the FDA or any other regulator.

The next decisive evidence will therefore come from the BiPASS results and the content and timing of Telix’s NDA submission. Fast Track can improve the efficiency of regulatory dialogue, but it does not guarantee approval, an accelerated decision or reimbursement for the proposed pre-biopsy use.